MA51914A - DOSAGE FORMS AND METHODS FOR OBTAINING ENANTIOMERICALLY ENRICHED OR PURE BUPROPION - Google Patents
DOSAGE FORMS AND METHODS FOR OBTAINING ENANTIOMERICALLY ENRICHED OR PURE BUPROPIONInfo
- Publication number
- MA51914A MA51914A MA051914A MA51914A MA51914A MA 51914 A MA51914 A MA 51914A MA 051914 A MA051914 A MA 051914A MA 51914 A MA51914 A MA 51914A MA 51914 A MA51914 A MA 51914A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- dosage forms
- enantiomerically enriched
- pure bupropion
- obtaining enantiomerically
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51914A true MA51914A (en) | 2020-12-30 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051914A MA51914A (en) | 2018-02-23 | 2019-02-25 | DOSAGE FORMS AND METHODS FOR OBTAINING ENANTIOMERICALLY ENRICHED OR PURE BUPROPION |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (en) |
| JP (2) | JP2021513998A (en) |
| KR (2) | KR20230075531A (en) |
| CN (1) | CN112087999A (en) |
| AU (2) | AU2019223187B2 (en) |
| BR (1) | BR112020017179A2 (en) |
| CA (1) | CA3092076A1 (en) |
| CL (1) | CL2020002166A1 (en) |
| CR (1) | CR20200415A (en) |
| EC (1) | ECSP20060179A (en) |
| IL (1) | IL276871A (en) |
| MA (1) | MA51914A (en) |
| MX (1) | MX2020008704A (en) |
| NI (1) | NI202000056A (en) |
| NZ (1) | NZ767378A (en) |
| PE (1) | PE20211752A1 (en) |
| SG (1) | SG11202008056SA (en) |
| WO (1) | WO2019165379A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| PE20221314A1 (en) * | 2019-09-20 | 2022-09-07 | Axsome Therapeutics Inc | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2318960A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| MEP3608A (en) * | 2003-08-08 | 2011-05-10 | Biovail Lab Int Srl | Modified-release tablet of bupropion hydrochloride |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
-
2019
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/en active Pending
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/en active Pending
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/en not_active IP Right Cessation
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/en unknown
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/en unknown
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en unknown
- 2019-02-25 CR CR20200415A patent/CR20200415A/en unknown
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/en active Application Filing
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/en unknown
- 2019-02-25 MA MA051914A patent/MA51914A/en unknown
-
2020
- 2020-08-21 NI NI202000056A patent/NI202000056A/en unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/en unknown
- 2020-08-23 IL IL276871A patent/IL276871A/en unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/en unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521A1/en active Pending
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019223187A1 (en) | 2020-09-17 |
| PE20211752A1 (en) | 2021-09-06 |
| NZ767378A (en) | 2024-03-22 |
| KR20230075531A (en) | 2023-05-31 |
| NI202000056A (en) | 2021-01-11 |
| WO2019165379A1 (en) | 2019-08-29 |
| CN112087999A (en) | 2020-12-15 |
| IL276871A (en) | 2020-10-29 |
| BR112020017179A2 (en) | 2020-12-22 |
| JP2022153638A (en) | 2022-10-12 |
| SG11202008056SA (en) | 2020-09-29 |
| CL2020002166A1 (en) | 2020-10-23 |
| JP2021513998A (en) | 2021-06-03 |
| AU2019223187B2 (en) | 2022-07-28 |
| EP3755312A1 (en) | 2020-12-30 |
| MX2020008704A (en) | 2020-12-07 |
| AU2022204521A1 (en) | 2022-07-21 |
| CA3092076A1 (en) | 2019-08-29 |
| KR20210003091A (en) | 2021-01-11 |
| EP3755312A4 (en) | 2022-03-16 |
| CR20200415A (en) | 2021-02-03 |
| ECSP20060179A (en) | 2020-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51914A (en) | DOSAGE FORMS AND METHODS FOR OBTAINING ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | |
| DK3551622T3 (en) | MODULATOR OF TRANSMEMBRANE CONDUCTANCE REGULATOR OF CYSTIC FIBROSE, PHARMACEUTICAL COMPOSITIONS, TREATMENT PROCEDURES AND METHOD OF MANUFACTURE OF THE MODULATOR | |
| MA42819A (en) | METHODS FOR THE TREATMENT OF ARENAVIRIDAE AND CORONAVIRIDAE VIRAL INFECTIONS | |
| MA43129A (en) | PROCESSES FOR THE TREATMENT OF PAIN OR FEVER USING PHARMACEUTICALLY ACTIVE ACETAMINOPHEN DIMERS BOUND THROUGH PHENOLIC HYDROXYL GROUPS | |
| MA50849A (en) | SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | |
| DK3347014T3 (en) | Methods for diagnosing and treating Tourette's syndrome | |
| EP3500248A4 (en) | Method and apparatus for the manufacture of fibrous dosage forms | |
| GB2576346B (en) | Water purifying apparatus and method | |
| MA45725A (en) | PLATE-SHAPED STRUCTURE, TANK AND PROCESS | |
| MA52960A (en) | COMPOSITIONS AND METHODS FOR THE REDUCTION OR TREATMENT OF FIBROSIS | |
| MA43758A (en) | METHODS FOR DETERMINING THE DOSAGE OF A THERAPEUTIC AGENT AND RELATED TREATMENTS | |
| PT3773615T (en) | Liquid composition for use in the treatment of the mucosa of the oro-pharyngo-laryngo-esophageal tract | |
| DE112018000064A5 (en) | Transport device and method and apparatus for producing the transport device | |
| DE112019003634T8 (en) | OPTOELECTRONIC COMPONENT AND THE METHOD FOR MANUFACTURING AN OPTOELECTRONIC COMPONENT | |
| DK3613281T3 (en) | CHEESE-MAKING APPARATUS | |
| MA49688A (en) | MYELODYSPLASIC SYNDROME TREATMENT METHODS | |
| ITUB20151800A1 (en) | METHOD AND APPARATUS FOR THE ACQUISITION OF PANORAMIC RADIOGRAPHIES AND VOLUMETRIC RADIOGRAPHIES CBCT | |
| MA55531A (en) | METHODS FOR THE TREATMENT OF BETA-THALASSEMIA | |
| DK3914258T3 (en) | COMPOSITION FOR THE TREATMENT OF PERIODONTITIS AND REGENERATION OF INTERDENTAL PAPI | |
| GB201908229D0 (en) | Microneedles and methods for the manufacture thereof | |
| GB2578272B (en) | Apparatus and method for the production of solid dosage forms | |
| DK3580549T3 (en) | ACCOMPANYING DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF CYSTIC FIBROSE WITH ALGINATOLIGOMERS | |
| DE112017005430A5 (en) | Liquid purification element, liquid purification system and method for producing a liquid purification element | |
| IL291514A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| GB201620484D0 (en) | Apparatus for interdental cleaning and method for manufacturing the same |